아토피 피부염 유사 NC/Nga 마우스 모델에서 유용 미생물 발효물질의 항염증효과

키워드

참고문헌 (35)

1. Spergel, J.M, "Atopic dermatitis and the atopic march", J Allergy Clin Immunol, 112(6), pp.S118~127 (2003)
2. Leung, D.Y, "Atopic dermatitis", Lancet, 361(9352), pp.151~160 (2003)
3. Leung, D.Y, "New insights into atopic dermatitis", J Clin Invest, 113, pp.651~657 (2004)
4. Mohrenschlager, M, "Atopic eczema: what's new?", J Eur Acad Dermatol Venereol, 20, pp.503~513 (2006)
5. Novak, N, "Allergic and nonallergic forms of atopic diseases", J Allergy Clin Immunol, 112, pp.252~262 (2003)
6. Schultz-Larsen, F, "Epidermiology of atopic dermatitis", Immunol Allergy Clin North Am, 22, pp.1~24 (2002)
7. Rollins, B.J, "Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1", JE, 1990, pp.136, 1229~1233
8. Power, C.A, "The chemokine system: novel broad-spectrum therapeutic targets", Curr Opin Pharmacol, 1, pp.417~424 (2001)
9. Pivarcsi, A, "Chemokine networks in atopic dermatitis: traffic signals of disease", Curr Allergy Asthma Rep, 5, pp.284~290 (2005)
10. Reiss, Y, "CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin", J Exp Med, 194, pp.1541~1547 (2001)
11. Nakazato, J, "Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis", Pediatr Allergy Immunol, 19, pp.605~613 (2008)
12. 정승일, "천연물 유래 Th2 케모카인 억제제 발굴에 의한 새로운 아토피 피부염 치료기술 개발 : 아토피 피부염 모델 NC", Nga 마우스에서 고삼 추출액의 억제 효과, 2009, pp.17(1), 141~151[DOI]
13. Gao, X.K, "Kampo Medicines for Mite Antigen-Induced Allergic Dermatitis in NC", Nga Mice, 2005, pp.2, 191~199
14. Park, E.K, "Antiinflammatory effects of a combined herbal preparation (RAH13) of Phellodendron amurense and Coptis chinensis in animal models of inflammation", Phytother Res, 21, pp.746~750 (2007)
15. Noh, S.U, "Epigallocatechin-3-gallate improves Dermatophagoides pteronissinus extract-induced atopic dermatitis-like skin lesions in NC", Nga mice by suppressing macrophage migration inhibitory factor, 2008, pp.28, 1172~1182
16. Seon Il Jang, "Wogonin inhibits Cytokine-induced TARC", CCL17 Expression by Suppression of NF-κB activation via p38 MAP kinase Signalning Pathways in HaCaT Keratinocytes, 2007, pp.21(4), 1017~1024[DOI]
17. 윤용갑1, 장선일2, "금은화 수용성 추출물의 LPS 유도 염증매개물 억제 효과", 대한본초학회지, 22(3), pp.117~125 (2007), 대한본초학회
18. CCL17 and MDC, "Sulforaphane suppresses IFN-γ and TNF-α-stimulated TARC", pp.J. Dermatol, CCL22 expression through heme oxygenase-1 and NF-κB in HaCaT keratinocytes
19. Higa, T, "Clinical and basic medical research on EMX" (2001), EMRO Okinawa
20. Chui, C.H, "Growth inhibitory potential of effective microorganism fermentation extract (EM-X) on cancer cells", Int J Mol Med, 14, pp.925~929 (2004)
21. Aruoma, O.I, "Assessment of the ability of the antioxidant cocktail-derived from fermentation of plants with effective microorganisms (EM-X) to modulate oxidative damage in the kidney and liver of rats in vivo: studies upon the profile of poly- and mono-unsaturated fatty acids", Toxicol Lett, 135, pp.209~217 (2002)
22. Deiana, M, "The antioxidant cocktail effective microorganism X (EM-X) inhibits oxidant-induced interleukin-8 release and the peroxidation of phospholipids in vitro", Biochem Biophys Res Commun, 296, pp.1148~1151 (2002)
23. Aruoma, O.I, "The antioxidant cocktail, effective microorganism X (EM-X), protects retinal neurons in rats against N-methyl-D-aspartate excitotoxicity in vivo", Free Radic Res, 37, pp.91~97 (2003)
24. Datla, K.P, "The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease", J Pharm Pharmacol, 56, pp.649~654 (2004)
25. Do, J.S, "Effective microorganism fermentation extract (EM-X) attenuates airway hyperreactivity and inflammation through selective inhibition of the TH2 response independently of antioxidant activity", Int J Mol Med, 220, pp.631~635 (2007)
26. Hanifin, J.M, "Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)", American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines", 2004, pp.50, 391~404
27. Matsuda, H, "Development of atopic dermatitis-like skin lesion with IgE-hyperproduction in NC", Nga mice, 1997, pp.9, 461~466
28. Yamamoto, M, "A Novel Atopic Dermatitis Model Induced by Topical Application with Dermatophagoides Farinae Extract in NC", Nga Mice, 2007, pp.56, 139~148
29. Tsunemi, Y, "CCL17 transgenic mice show an enhanced Th2-type response to both allergic and non-allergic stimuli", Eur J Immunol, 36, pp.2116~2127 (2006)
30. Sebastiani, S, "CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first beta-strand of chemokine", Eur J Immunol, 35, pp.746~756 (2005)
31. Reiss, Y, "CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin", J Exp Med, 194, pp.1541~1547 (2001)
32. Homey, B, "CCL27-CCR10 interactions regulate T cell-mediated skin inflammation", Nat Med, 8, pp.157~165 (2002)
33. Oshio, T, "Dermatophagoides farinae extract induces severe atopic dermatitis in NC", Nga mice, which is effectively suppressed by the administration of tacrolimus ointment, 2009, pp.9, 403~411
34. Nakazato, J, "Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis", Pediatr Allergy Immunol, 19, pp.605~613 (2008)
35. Vestergaard, C, "Overproduction of Th2-specific chemokines in NC", Nga mice exhibiting atopic dermatitis-like lesions, 1999, pp.104, 1097~1105

관련 논문AI추천